Clinical Trial Technology Opportunity Assessment

December 6, 2021 Summer Foote

A senior director in R&D at an F100 pharma company wanted to conduct a landscape analysis of technology trends and innovation impacting Phase 3 clinical trials in immunology to improve speed, effectiveness, and patient/provider experience.

BTG delivered a digital health strategy consultant with 20+ years of diverse strategic advisory, market access, and competitive intelligence experience. The consultant had previously spearheaded a range of initiatives for top biopharma companies to inform digital health and launch strategies. On this project, the consultant identified key players and areas of opportunity, anticipated disruptive competitor developments, and pinpointed ways to achieve competitive advantage. The output delivered by the talent served to inform the digital health strategy for the Immunology R&D team.

Previous Article
On-Demand Talent for Innovation, Transformation, and Growth in Life Sciences
On-Demand Talent for Innovation, Transformation, and Growth in Life Sciences

Independent talent provide an agile source of critical skills that allow life science leaders to keep pace ...

Next Article
Flexible Project Management for Pre-Clinical and Clinical Drug Development
Flexible Project Management for Pre-Clinical and Clinical Drug Development

With a wealth of promising treatments in development at any time, life science companies need strong projec...

Get our free guide to working with on-demand talent.

Read Now